Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

ABSTRACT:

Context

Obesity is associated with reduced GH secretion and increased cardiovascular disease risk.

Objective

We performed this study to determine the effects of augmenting endogenous GH secretion on body composition and cardiovascular disease risk indices in obese subjects with reduced GH secretion.

Design, patients and methods

A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion. Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months. Abdominal visceral adipose tissue (VAT) was assessed by abdominal computed tomography scan, and carotid intima-media thickness (cIMT) was assessed by ultrasound. Treatment effect was determined by longitudinal linear mi

SUBMITTER: Makimura H 

PROVIDER: S-EPMC3513535 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature